Lasmiditan Dosage

Medically reviewed by Drugs.com. Last updated on Sep 20, 2024.

Usual Adult Dose for Migraine

Initial dose: 50 mg, 100 mg, or 200 mg orally once
Maximum dose: 1 dose per day

Comments:

• This drug should not be taken unless the patient can wait 8 hours or more before driving or operating machinery.
• No more than 1 dose should be taken in 24 hours; a second dose has not been shown to be effective for the same migraine attack.
• The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
• This drug is not indicated for the prevention of migraine attacks.

Use: For the acute treatment of migraine with or without aura.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Not recommended

Dose Adjustments

Elderly: Dose selection should be cautious, generally starting at the low end of the dosing range

Precautions

CONTRAINDICATIONS:

• None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule V

Dialysis

Data not available

Other Comments

Administration advice:

• Take orally with or without food; swallow tablets whole, do not split, crush, or chew
• Do not take more than 1 dose in a 24 hour period; the safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established
• Patients should wait at least 8 hours after dosing before driving or operating machinery

General:

• In a human abuse potential study, this drug showed statistically significantly higher "drug liking" scores than placebo and statistically significantly lower scores compared to alprazolam 2 mg; euphoric mood occurred to a similar extent with lasmiditan doses of 200 mg and 400 mg and alprazolam 2 mg (43% to 49%).
• Concomitant use with other CNS depressant drugs has not been evaluated in clinical studies.
• Patients should understand that they may not be able to assess their own driving competence and the degree of impairment caused by this drug; if they are unable to wait 8 hours or more before driving a motor vehicle or operating machinery, they should not take this medication.

Monitoring:

• Monitor for risk of drug abuse and signs of misuse or abuse
• Monitor heart rate in patients for whom changes in heart rate may be problematic
• Monitor blood pressure in patients for whom increased blood pressure not be tolerated

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Patients should be instructed to avoid driving or operating machinery for at least 8 hours after taking a dose; if they are not able to wait the necessary time, they should not take a dose.

Frequently asked questions

• What are the new drugs for the treatment of migraine?

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer